Back to Agenda
[V6-S1] What is Needed for Further Promotion of Drug Discovery and Development from Academia?
Session Chair(s)
Masaru Iwasaki, MD, PHD
Vice President, Head of Center for Advancing Clinical Research (CACR), University of Yamanashi, Japan
It has been more than one year since AMED was established with the goal of promoting the commercialization of innovative seeds from academia. After AMED’s establishment, new efforts beyond the conventional framework were started. Although certain results are achieved, there still remain further challenges in advancing drug discovery and development from academia. In this session, experts from each stakeholder (AMED, academia, pharmaceutical companies, PMDA) will discuss the issues to be addressed and measures which further promote drug discovery and development from academia.
Speaker(s)
Ken Ishii, MD, PHD
Director, Department of Research Promotion, Japan Agency for Medical Research and Development (AMED), Japan
How and What to Develop, Innovate and Advance AMED
Yoichi Nakanishi, MD, PHD
Professor and Director, Research Institute for Diseases of Chest, Kyushu University, Japan
Strategy to Boost Drug Discovery and Development from Academia; What’s the Issue?
Jin Shiomura
Managing Director and Chief Executive Officer, Nobelpharma Co., Ltd., Japan
Companies and Drug Discovery by Academia
Noriatsu Kono, MPHARM
Organizational management, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Pharmaceutical Affairs Consultation on R&D Strategy (Yakuzi-senryaku-Consultation) & SAKIGAKE (Review of Breakthrough products)
Have an account?